Immuron (IMRN) Net Income towards Common Stockholders (2016 - 2025)
Immuron (IMRN) posted Net Income towards Common Stockholders of -$3.3 million for Q2 2025, down 7126.84% on a QoQ basis from -$46223.4 in Q3 2024, and up 26.93% year-over-year from -$2.6 million in Q2 2024.
Powered by 
Analysis
Immuron (IMRN) Net Income towards Common Stockholders (2016 - 2025) Analysis & Trends
Immuron has reported Net Income towards Common Stockholders for 10 years, with the latest figure at -$3.3 million in Q2 2025.
- On a quarterly basis, Net Income towards Common Stockholders rose 26.93% year-over-year to -$3.3 million in Q2 2025; TTM through Jun 2025 was -$8.0 million, a 29.02% decrease from a year earlier, with the FY2026 full-year figure at -$3.8 million, down 7207.34% from the prior year.
- Net Income towards Common Stockholders was -$3.3 million for Q2 2025 at Immuron, down from -$46223.4 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$13260.2 in Q4 2021, with the low at -$6.5 million in Q2 2021.
- Average Net Income towards Common Stockholders over 5 years is -$2.0 million, with a median of -$795595.5 recorded in 2022.
- The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders slumped 2558.11% in 2022, then jumped 93.01% in 2023.
- Over 5 years, Net Income towards Common Stockholders stood at -$13260.2 in 2021, then plunged by 2558.11% to -$352470.5 in 2022, then surged by 93.01% to -$24649.8 in 2023, then tumbled by 87.52% to -$46223.4 in 2024, then plunged by 7126.84% to -$3.3 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$3.3 million (Q2 2025), -$46223.4 (Q3 2024), and -$4.6 million (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 221.78 Bn | 207.79 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 189.46 Bn | 186.20 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.47 Bn | 122.62 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 82.64 Bn | 74.65 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Moderna | 72.84 Bn | 67.70 Bn | 52.00 Mn | -782.00 Mn |
| 6 | Argenx Se | 59.64 Bn | 54.46 Bn | 1.37 Bn | 472.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.65 Bn | 30.35 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 33.30 Bn | 32.01 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 27.62 Bn | 28.31 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Immuron | 7.31 Mn | -1.71 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -3.34 Mn |
| Sep 9, 2024 | -46,223.37 |
| Jun 30, 2024 | -4.57 Mn |
| Dec 31, 2023 | -24,649.80 |
| Jun 30, 2023 | -1.24 Mn |
| Dec 31, 2022 | -352,470.52 |
| Dec 31, 2021 | -13,260.17 |
| Jun 30, 2021 | -6.46 Mn |
| Dec 31, 2020 | -41,946.68 |
| Jun 30, 2020 | -1.92 Mn |
| Dec 31, 2019 | -15,212.27 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | 3.79 Mn |
| Dec 31, 2016 | 2.57 Mn |
| Jun 30, 2016 | -3.28 Mn |
API Access
Immuron Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=IMRN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "IMRN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=IMRN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();